RE:Lets not lose sight of the facts.This is true, however, the market shows concern about the balance sheet and the confidence in the management. At the AGM, Bruce Pritchard should come with a plan to reduce the cash burn and he should adress the concern about the balance sheet with different option like selling the 20 millions$ of plasma inventory completed by a small financing in order to strenghten the balance sheet enough and be in a better position to negociate a deal. A financing will be painful compare to the previous one, but if that is what it takes to get us a better deal with a partner, then so be it. Other big pharma have billions of shares. Shorts are not cover yet so they will still put down pressure and banks smell a financing coming. If I look at the past financing, banks always do what it takes to keep the SP low and they do a financing with a 15% discount. That's the game. Once it will be done, then the SP will slowly recover. And once they sign a deal with a serious partner, then the SP will climb back to reflect more the IP value because the balance sheet concern will be out of the equation and the confidence in the management will come back right away and investor will focus on the most important part, the pipeline and the revenu projection instead. We are in the perfect storm and we shall remain there until a deal is done. after that, this should be blue sky. In the meantime, if you have liquidity, it remains an excellent entry point IMO and there might be even better entry point if a financing as to be done before a deal is completed and until the short position is covered
IMHO, Eric.